AMGN:NGS-Amgen Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 205.10

Change

+1.90 (+0.94)%

Market Cap

USD 132.81B

Volume

2.23M

Yahoo Analyst Target

USD 204.05 (-0.51%)

STA Analyst Target

USD 201.81 (-1.61%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. The Company's business segment is human therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
GILD Gilead Sciences Inc.

+0.95 (+1.29%)

USD 97.01B
BIIB Biogen Inc.

+2.33 (+0.69%)

USD 68.74B
CELG Celgene Corporation

+0.92 (+1.05%)

USD 62.11B
SHPG Shire plc

+1.40 (+0.78%)

USD 47.05B
VRTX Vertex Pharmaceuticals Incorpo..

+3.92 (+2.22%)

USD 46.13B
REGN Regeneron Pharmaceuticals Inc.

+3.55 (+0.93%)

USD 41.84B
ALXN Alexion Pharmaceuticals Inc.

+2.64 (+2.16%)

USD 27.77B
BMRN BioMarin Pharmaceutical Inc.

+0.63 (+0.63%)

USD 17.83B
GRFS Grifols S.A.

+0.31 (+1.47%)

USD 14.63B
INCY Incyte Corporation

+1.03 (+1.53%)

USD 14.51B

ETFs Containing AMGN

BBH VanEck Vectors Biotech ET.. 9.54 % 0.35 %

+1.89 (+1.44%)

USD 0.46B
IBB iShares Nasdaq Biotechnol.. 7.91 % 0.47 %

+1.63 (+1.39%)

USD 9.42B
BIB ProShares Ultra Nasdaq Bi.. 6.13 % 0.95 %

+1.81 (+2.78%)

USD 0.38B
HHL.U:CA Harvest Healthcare Leader.. 5.04 % 0.00 %

+0.07 (+0.81%)

CAD 0.03B
HHL:CA Harvest Healthcare Leader.. 5.04 % 1.24 %

+0.07 (+0.81%)

CAD 0.28B
UBIO Proshares UltraPro Nasdaq.. 5.03 % 0.95 %

+1.66 (+4.17%)

USD 0.03B
LIFE.B:CA Evolve Global Healthcare .. 5.00 % 0.67 %

N/A

CAD 1.04M
LIFE:CA Evolve Global Healthcare .. 5.00 % 0.66 %

N/A

CAD 1.46M
PJP Invesco Dynamic Pharmaceu.. 4.92 % 0.57 %

+0.84 (+1.16%)

USD 0.59B
PBE Invesco Dynamic Biotech &.. 4.66 % 0.59 %

+0.84 (+1.46%)

USD 0.32B
HUL:CA Harvest US Equity Plus In.. 3.88 % 1.86 %

+0.10 (+1.04%)

CAD 0.01B
XLV SPDR Select Sector Fund -.. 3.69 % 0.14 %

+0.91 (+0.97%)

USD 19.03B
JHMH John Hancock Multifactor .. 3.65 % 0.50 %

+0.35 (+1.00%)

USD 0.06B
PILL Direxion Daily Pharmaceut.. 3.54 % 0.00 %

+0.84 (+2.38%)

USD 5.42M
IYH iShares U.S. Healthcare 3.45 % 0.43 %

+1.82 (+0.91%)

USD 2.32B
FHLC Fidelity MSCI Health Care.. 3.16 % 0.08 %

+0.44 (+0.96%)

USD 1.47B
LNGR Global X Longevity Themat.. 3.12 % 0.52 %

+0.04 (+0.16%)

N/A
VHT Vanguard Health Care 3.10 % 0.10 %

+1.60 (+0.90%)

USD 8.83B
HAU:CA Horizons Active US Divide.. 3.10 % 0.80 %

-0.01 (-0.08%)

CAD 6.32M
SHE SPDR Series Trust SSGA Ge.. 3.09 % 0.20 %

+0.61 (+0.79%)

USD 0.36B
QDYN FlexShares Quality Dynami.. 2.62 % 0.37 %

+0.25 (+0.55%)

USD 0.05B
IXJ iShares Global Healthcare 2.58 % 0.47 %

+0.64 (+1.03%)

USD 1.76B
QLC FlexShares US Quality Lar.. 1.90 % 0.32 %

+0.36 (+0.99%)

USD 0.06B
FDRR Fidelity Dividend ETF for.. 1.71 % 0.29 %

+0.23 (+0.71%)

USD 0.38B
HECO Strategy Shs EcoLogical 1.63 % 0.95 %

+0.18 (+0.41%)

USD 0.01B
RFDA RiverFront Dynamic US Div.. 1.51 % 0.52 %

+0.19 (+0.55%)

USD 0.15B
CVY Invesco Zacks Multi-Asset.. 1.09 % 0.65 %

+0.18 (+0.80%)

USD 0.28B
VGFO Virtus WMC Global Factor .. 0.89 % 0.49 %

N/A

USD 5.35M
ONEQ Fidelity Nasdaq Composite.. 0.00 % 0.21 %

+3.00 (+0.96%)

USD 1.67B
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

+1.94 (+1.73%)

USD 0.16B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.94% 67% D+ 71% C-
Dividend Return 2.28% 43% F 73% C
Total Return 20.22% 68% D+ 72% C-
Trailing 12 Months  
Capital Gain 9.00% 61% D- 53% F
Dividend Return 2.72% 71% C- 66% D
Total Return 11.71% 62% D- 55% F
Trailing 5 Years  
Capital Gain 75.52% 73% C 65% D
Dividend Return 15.94% 57% F 67% D+
Total Return 91.46% 76% C 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 12.37% 58% F 62% D-
Dividend Return 14.83% 60% D- 65% D
Total Return 2.47% 53% F 63% D
Risk Return Profile  
Volatility (Standard Deviation) 15.81% 94% A 73% C
Risk Adjusted Return 93.85% 98% A+ 81% B-
Market Capitalization 107.37B 100% A+ 100% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 54.84 1% F 8% F
Price/Book Ratio 8.52 24% F 14% F
Price / Cash Flow Ratio 3.21 8% F 38% F
Price/Free Cash Flow Ratio 13.40 7% F 37% F
Management Effectiveness  
Return on Equity 10.75% 84% B 70% C-
Return on Invested Capital 18.66% 89% B+ 84% B
Return on Assets 3.16% 92% A- 72% C-
Debt to Equity Ratio 177.50% 8% F 12% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

AMGN:NGS-Amgen Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 205.10

Change

+1.90 (+0.94)%

Market Cap

USD 132.81B

Volume

2.23M

Yahoo Analyst Target

USD 204.05 (-0.51%)

STA Analyst Target

USD 201.81 (-1.61%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-09-20